Obesity: A main factor of metabolic syndrome?

Panminerva Medica

Volumn 48, Issue 2, 2006, Pages 77-85

  Licata, G ^a,b   Argano, C ^a   Di Chiara, T ^a   Parrinello, G ^a   Scaglione, R ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Divisione Medicina Interna e Specialistica   (Italy)

Author keywords

Cardiovascular diseases; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

FATTY ACID;

ADIPOSE TISSUE; ANIMAL; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; OBESITY; REVIEW;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY;

EID: 33750574972     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Kylin E. Hypertonie-Hyperglikamie-Hyperurikamies syndrome. Zentralblatt fur Innere Medizin 1923;44.
2. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia 1965;1:137.
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
4. The International Diabetes Federation consensus worldwide definition of the metabolic syndrome. www.idf.org
5. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 2005;1:39-59.
6. Licata G, Corrao S, Parrinello G, Scaglione R. Obesità e malattie cardiovascolari. In: Atti del 93° Congresso Nazionale della Società Italiana di Medicina Interna. Firenze 17-21 Ottobre 1992. Roma: L. Pozzi Editore; 1992. p. 1-193.
7. Licata G, Corrao S, Parrinello G, Scaglione R. Obesity and cardiovascular diseases. Amsterdam: Excerpta Medica; 1996.
8. Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesite. Press Med 1947;30:339-40.
9. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation: Part 1. WHO/NCD/NCS/ 99.2. Geneva: WHO; 1999. p. 31-3.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
12. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscl Thromb Vasc Biol 2005;25:2243-4.
13. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a world-wide definition. A consensus statement of the International Diabetes Federation. Diabet Med 2006;23:469-80.
14. Lyon CJ, Law RE, Hsueh WA. Adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-200.
15. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
16. World Health Organization. Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 1998.
17. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 1989;38:1595-601.
18. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003;46:1297-312.
19. Tchernof A, Lamarche B, Prud'Homme D. The dens LDL phenotype. Association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.
20. Das M, Gabriely I, Barzilai N. Caloric restriction, body fat and ageing in experimental models. Obes Rev 2004;5:13-9.
21. Fasshauer M, Paschke R. Regulation of adypocytokines and insulin resistance. Diabetologia 2003;46:1594-603.
22. Diez JJ, Iglesias P. The role of novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
23. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein- cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991;87;536-44.
24. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
25. Dandona P, Aljada A, Chaudhurui A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005;111:1448-542.
26. Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S et al. Haemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism 1995;44:1417-21.
27. Licata G, Di Chiara T, Licata A, Triolo G, Argano C, Parrinello G et al. Relationship between circulating E-selectin, DD genotype of angiotensin converting enzyme, and cardiovascular damage in central obese subjects. Metabolism 2003;52:999-1004.
28. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signalling. J Clin Invest 1996;97:2569-75.
29. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87:2246-52.
30. Licata G, Volpe M, Scaglione R, Rubattu S. Salt regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994;23 Suppl I:20-4.
31. McNeill AM, Schmidt MI, Rosamond WD, East HE, Girman CJ, Ballantyne CM et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385-90.
32. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-76.
33. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097-105.
34. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002;347: 358-9.
35. Larsson B, Svardsudd K, Welin L. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and heart: 13-year follow-up of participants in the study of men born in 1913. BMJ 1984;288:1401-4.
36. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654-64.
37. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907-15.
38. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. N Engl J Med 1992;327:1350-5.
39. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
40. VanGaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
41. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004;139: 1088-92.
42. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-221.
43. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005;310:314-7.
44. Thompson PD, Buchner D, Pina IL. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.
45. PROactive: Prospective pioglitazone clinical trial in macrovascular events. www.proactive-results.com.
46. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004;27:1015.